IL1B and myocardial infarction: In contrast, in the recent CANTOS trial an anti-IL-1β monoclonal antibody (canakinumab) reduced HF-related hospitalizations and mortality in patients with previous myocardial infarction (21), but the system-wide effects and mechanisms of action remain undefined.